Loading…
Tonix Pharmaceuticals Holding Corp. is projected to rise to $13.12 by 2027, a +31% move from its current price of $10.01. TNXP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $9.61 | $10.02 | $10.45 | +0.14% |
| Aug 5 | $9.46 | $10.04 | $10.65 | +0.29% |
| Aug 6 | $9.35 | $10.05 | $10.81 | +0.43% |
| Aug 7 | $9.26 | $10.07 | $10.95 | +0.58% |
| Aug 8 | $9.18 | $10.08 | $11.08 | +0.72% |
| Aug 9 | $9.11 | $10.10 | $11.19 | +0.87% |
| Aug 10 | $9.05 | $10.11 | $11.30 | +1.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.05 | $10.11 | $11.30 | +1.01% |
| Week 2 | $8.73 | $10.21 | $11.95 | +2.03% |
| Week 3 | $8.51 | $10.32 | $12.51 | +3.07% |
| Week 4 | $8.34 | $10.42 | $13.02 | +4.11% |
| Week 5 | $8.21 | $10.53 | $13.50 | +5.16% |
| Week 6 | $8.10 | $10.63 | $13.96 | +6.22% |
| Week 7 | $8.00 | $10.74 | $14.41 | +7.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company. The company develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
It offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
The company develops a broad pipeline across multiple therapeutic areas, including TNX-102 SL and other TNX programs such as TNX-1300, TNX-1500, TNX-4800, TNX-2900, TNX-4900, TNX-1700, TNX-1800, and TNX-1850, aimed at CNS, immunology, infectious diseases, and autoimmune conditions.
Tonix Pharmaceuticals Holding Corp. (TNXP) is currently priced at $9.88 with a market cap of $157.5M and is ranked 3758 in market capitalization. The stock is trading in a smaller-cap segment with a price that sits below key moving averages.
The price is below the SMA50 of $12.32 and the SMA200 of $15.19, which provides context for near-term price dynamics. The overall price outlook is supported by a long-term forecast showing bullish momentum after 2026, with the 2027 average price projected at $12.69 and the 2050 average at $47.49, while the 2050 maximum could reach $106.40.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 5.0% below — buyers have tended to step in here.
The nearest ceiling, 32.1% above — a clean break opens room to run.
A major ceiling 57.2% above — clearing it would confirm fresh momentum.
Key TNXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TNXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.98 | Buy | $10.06 | Sell |
| MA 10 | $10.36 | Sell | $10.40 | Sell |
| MA 20 | $11.30 | Sell | $10.95 | Sell |
| MA 50 | $11.81 | Sell | $11.80 | Sell |
| MA 100 | $12.78 | Sell | $13.02 | Sell |
| MA 200 | $14.82 | Sell | $31.37 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.24 | Neutral |
| Stoch RSI (14) | 29.66 | Neutral |
| CCI (20) | -86.46 | Neutral |
| Williams %R (14) | -82.88 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -13.78 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 17.12 | Buy |
| TRIX (15) | -0.56 | Sell |
| Awesome (5,34) | -1.68 | Sell |
| Ultimate (7,14,28) | 39.67 | Neutral |
| Momentum (10) | -2.42 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 9.70 | Buy |
| ADX (14) | 15.60 | Neutral |
| ATR (14) | 0.47 | Info |
Bearish sentiment dominates near-term momentum. RSI14 is 40, indicating modest momentum to the downside.
The stock trades below the 50-day and 200-day moving averages, with SMA50 at $12.32 and SMA200 at $15.19. Support is marked at $10.59 and resistance at $13.22, outlining a near-term trading range.
Over the last 30 days, the price has ranged from a low of $7.45 to a high of $13.11, illustrating a broad, choppy short-term landscape. Annualized volatility sits at 80%, underscoring substantial price swings in this period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.51 | $10.01 | $16.46 | 0% | Neutral | |
| $9.96 | $13.12 | $18.56 | +31% | Bullish | |
| $9.95 | $13.74 | $20.51 | +37% | Bullish | |
| $9.56 | $13.71 | $21.33 | +37% | Bullish | |
| $8.82 | $13.10 | $21.10 | +31% | Bullish | |
| $8.22 | $12.61 | $20.91 | +26% | Bullish | |
| $8.07 | $12.75 | $21.71 | +27% | Bullish | |
| $10.10 | $16.42 | $28.62 | +64% | Bullish | |
| $11.17 | $18.68 | $33.27 | +87% | Bullish | |
| $10.85 | $18.62 | $33.84 | +86% | Bullish | |
| $10.83 | $21.05 | $41.54 | +110% | Bullish | |
| $18.98 | $42.18 | $93.56 | +321% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.51 | $10.01 | $13.13 | +0.00% |
| September 2026 | $9.49 | $11.40 | $14.21 | +13.93% |
| October 2026 | $9.40 | $11.41 | $14.45 | +0.08% |
| November 2026 | $9.67 | $11.84 | $15.19 | +3.77% |
| December 2026 | $10.27 | $12.69 | $16.46 | +7.12% |
Click any year to see its month-by-month TNXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TNXP is projected to trade between $9.51 and $16.46, averaging $10.01 — a potential gain of 0% from today's $10.01. A consolidation phase looks the most probable path here.
Tonix Pharmaceuticals Holding Corp.'s 2027 outlook centres on $13.12, within a $9.96 to $18.56 range. That is up +31% on the projected 2026 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2028, TNXP could reach as high as $20.51, with a base case around $13.74 and support toward $9.95 — roughly +37% from $10.01. Buyers look set to stay in control over this stretch.
Expect TNXP to range from $9.56 to $21.33 through 2029. The $13.71 average target implies a +37% move from current prices. That is 0% versus the projected 2028 average. Momentum favours further upside here.
The TNXP price prediction for 2030 points to an average of $13.10 (low $8.82, high $21.10) — a potential gain of +31% on today's $10.01. Buyers look set to stay in control over this stretch.
In 2031, TNXP is projected to trade between $8.22 and $20.91, averaging $12.61 — a potential gain of +26% from today's $10.01. That is -4% versus the projected 2030 average. Momentum favours further upside here.
Tonix Pharmaceuticals Holding Corp.'s 2032 outlook centres on $12.75, within a $8.07 to $21.71 range. That is up +1% on the projected 2031 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TNXP could reach as high as $28.62, with a base case around $16.42 and support toward $10.10 — roughly +64% from $10.01. Momentum favours further upside here.
Expect TNXP to range from $11.17 to $33.27 through 2034. The $18.68 average target implies a +87% move from current prices. That is up +14% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TNXP price prediction for 2035 points to an average of $18.62 (low $10.85, high $33.84) — a potential gain of +86% on today's $10.01. Momentum favours further upside here.
In 2040, TNXP is projected to trade between $10.83 and $41.54, averaging $21.05 — a potential gain of +110% from today's $10.01. That is up +13% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Tonix Pharmaceuticals Holding Corp.'s 2050 outlook centres on $42.18, within a $18.98 to $93.56 range. That is up +100% on the projected 2040 average. That marks a +321% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TNXP today (≈ 99.9001 TNXP) could be worth
$4,213.67
+$3,213.67 (+321%) by 2050 · US Dollar
Based on the average projected TNXP price of $42.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TNXPwould be worth at today's price.
$1,000 invested in TNXP on Jul 31, 2025 (≈ 26.539278 TNXP) would be worth
$265.66
-$734.34 (-73.4%) today · 0.27× · US Dollar
Based on a TNXP entry price of $37.68 vs. today's $10.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.88 | $1,013.16 | +1.3% |
| 1 month ago | $12.44 | $804.66 | -19.5% |
| 3 months ago | $13.6 | $736.03 | -26.4% |
| 6 months ago | $17.21 | $581.64 | -41.8% |
| 1 year ago | $37.68 | $265.66 | -73.4% |
| All time (5.0y) ago | $422,400 | $0.02 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TNXP forecast.
Our base-case forecast reaches $20.00 around 2040.
Implied market cap at $20.00: $318.82M
The multi-year forecast paints a bullish trajectory for TNXP after 2026. In 2026, the min price is $9.88, the avg is $9.88, and the max is $16.56, with a neutral sentiment. From 2027 onward, the model shows a bullish stance, with the 2027 avg at $12.69 and a 2027 max of $18.05, delivering a 28.4% ROI.
The uptrend continues through 2028 (avg $13.71, max $20.58, ROI 38.7%), 2029 (avg $13.82, max $21.63, ROI 39.9%), and 2030 (avg $12.94, max $20.96, ROI 30.9%). The 2031 and 2032 forecasts keep a bullish tone (avg $13.09 and $13.82; max $21.86 and $23.69; ROI 32.5% and 39.9%). In 2033 the avg rises to $17.88 with a max of $31.39 and an ROI of 80.9%.
2034 points to an avg of $20.37 and a max of $36.57 (ROI 106.2%), while 2035 shows an avg of $19.83 and a max of $36.33 (ROI 100.8%). By 2040, the forecast envisions an avg price of $24.75 with a max of $49.26 and a strong ROI of 150.5%. The 2050 outlook is particularly bullish, with an avg of $47.49, a max of $106.40 and a remarkable ROI of 380.7% as sentiment remains bullish.
These forecasts suggest a sustained upward trajectory long term, but they are estimates and not guarantees. Investors should consider that outcomes can vary and that risks exist in applying these projections to actual investment results.
Tap a question to reveal the answer.
The average price in 2030 is $12.94, with a min of $8.65 and a max of $20.96. The forecast also shows a 30.9% ROI and bullish sentiment for that year.
The forecast shows bullish sentiment from 2027 onward, with the average price rising to $12.69 in 2027, $12.94 in 2030, and up to $47.49 by 2050. The max price in 2050 is $106.40 and the ROI reaches 380.7%. These are estimates, not guarantees.
Yes. The 2050 max forecast is $106.40, which exceeds $50; note that 2040 max is $49.26, just under $50, while 2050 shows a peak well above $50.
The current price is $9.88 and the market cap is $157.5M.
The 30-day range is $7.45 to $13.11, and the annualized volatility is 80%.
Tonix Pharmaceuticals Holding Corp. Community Discussion
0Share your Tonix Pharmaceuticals Holding Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.